4 treatments across two clinical pathways. Each entry explains what the treatment is, how it is assessed and what it cannot do. Select any you would like to discuss and send them as one consultation request.
Consultation required for every treatment
Every treatment listed here requires assessment by a licensed healthcare professional. Selecting a treatment does not order it, reserve it, confirm suitability or create a prescription.
4 treatments shown
Tirzepatide
A prescription medicine containing tirzepatide, which acts on two gut-hormone receptors involved in appetite and blood-sugar regulation. Suitability, dose and monitoring are decided by a clinician.
Consultation required · Prescription only
Semaglutide
A prescription weight-management medicine containing semaglutide, a GLP-1 receptor agonist that influences appetite signalling. Prescribed only after a clinical assessment and used with ongoing follow-up.
Consultation required · Prescription only
Aqualyx
An injectable treatment discussed for small, discrete pockets of fat in a defined area. It is a contouring treatment, not a weight-management medicine, and is assessed area by area.
Consultation required
Fat-Burning Injections
Injectable formulations combining compounds such as B-group vitamins and amino acids. Often called fat-burning injections, though evidence for that effect is limited — a clinician will set realistic expectations.
Consultation required
Prescription-only medicines that act on appetite and metabolic signalling, used as part of a supervised weight-management plan. They are never dispensed on request: a licensed clinician reviews your medical history, current medicines and overall suitability first, and may recommend a different approach or none at all.
Treatments discussed for small, discrete areas or as an adjunct alongside diet, activity and clinical follow-up. These are not weight-management medicines and are not an alternative to a supervised weight-management plan — a clinician will explain where each one does and does not apply.
People often arrive with a specific product in mind, usually one they have seen discussed online. That is a perfectly reasonable starting point for a conversation, but it is not how the decision is made. A clinician works from your history, your current medicines, your previous attempts and an examination — and sometimes concludes that the treatment you asked about is not the right one, or that none of them is.
Clinical studies can compare average outcomes, but they do not predict your individual result. A clinician considers likely benefits, possible side effects, current health conditions, medicines and family history when discussing suitable options. The most talked-about treatment is not automatically the most appropriate one.
Mounjaro contains tirzepatide, which acts on GIP and GLP-1 receptors. Wegovy contains semaglutide, a GLP-1 receptor agonist. They are different medicines, not interchangeable selections. EMA product information describes these mechanisms in the EU; it does not confirm UAE registration or your suitability. A clinician must check the current local product information and assess you individually.
No. A localized contouring treatment addresses the shape of one small area. It does not affect body weight, appetite or metabolic health. If overall weight is your concern, a supervised weight-management consultation is the appropriate pathway.
No. Nothing here is purchasable, and treatment costs depend on what a clinician actually recommends after assessing you. Any figure published before that assessment would be speculative.
No. Adding a treatment builds a shortlist for your consultation. It does not order or reserve a medicine, confirm suitability, or create a prescription.
Send a consultation request and a member of the clinical team will contact you to discuss whether any of these treatments is appropriate for you.
